Pancreatic cancer is another highly lethal disease for which mortality closely parallels incidence [70], and the major driver gene KRAS is currently not druggable except for some early responses with Sotorasib treatment in those 1–2% of patients carrying the KRAS p.G12C mutation [71]. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.